GlassScriptPhysician profile
Genus Camilo Sarabia
NPI 1720647944
$7,530.24
in general payments reported to CMS, 2019-2025
19 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,093 · 2022: $2,489 · 2023: $1,193 · 2024: $1,356 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,948.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,528.21 | 2021-2025 | Cabenuva, Dovato, Apretude |
| Abbvie INC. | $980.12 | 2021-2025 | |
| Melinta Therapeutics, LLC | $817.96 | 2021-2025 | Rezzayo, Kimyrsa, Vabomere |
| Biohaven Pharmaceuticals, INC. | $800.00 | 2021 | |
| Gilead Sciences, INC. | $759.99 | 2021-2025 | Yeztugo |
| Merck Sharp & Dohme LLC | $698.41 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Paratek Pharmaceuticals, INC. | $652.52 | 2021-2025 | Nuzyra |
| Shionogi INC | $356.01 | 2021-2025 | Fetroja |
| Theratechnologies INC. | $254.96 | 2021-2023 | Egrifta, Trogarzo |
| Merz North America, INC. | $168.50 | 2022 | |
| Janssen Biotech, INC. | $141.74 | 2021-2022 | |
| Galderma Laboratories, L.P. | $100.00 | 2022 | |
| Janssen Products, LP | $65.99 | 2022 | |
| Solventum Corporation | $58.67 | 2024 | Activ.A.C. |
| Ferring Pharmaceuticals INC. | $54.94 | 2022-2023 | Rebyota |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $38.72 | 2021-2023 | Vibativ |
| Napo Pharmaceuticals INC | $31.70 | 2023 | Mytesi |
| Astellas Pharma US INC | $17.75 | 2021 | |
| Biomerieux INC | $4.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Genus Sarabia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.